In cells derived from CRC patients, low FTO induced a pan-elevation in m6A levels, and promoted in vivo tumorigenicity and chemoresistance of CRC cells, suggesting FTO as an anti-CRC factor16. The gene discussed is FTO; the disease is colorectal carcinoma.